Friday 13th August 2004 |
Text too small? |
One company with loads of groundbreaking research behind it; a ton of potential but no actual earnings is Pacific Edge Biotechnology.
Pacific Edge has been developing products for cancer treatment, an area of research where progress can be measured in years.
The shares have jumped up and down a bit lately on news that the company is close to signing a breakthrough deal with a Japanese pharmaceutical company, which could offer multimillion-dollar investment.
This is pretty good news because at balance date in March the company's capital was $9.62 million, accumulated deficit was $7.09 million, leaving shareholders' equity of $2.52 million.
That has since been boosted by a private placement of six million shares, raised by brokers Forsyth Barr.
But the company is burning through $1.4 million a year, according to chairman Trevor Scott.
If the Japanese deal goes through, and the company is negotiating with two other firms there as well, Pacific Edge could secure development work for at least four years and be able to fund more oncology tests.
The company, based near the University of Otago, has developed an extensive oncology database to correlate clinical information on cancer progression.
No comments yet
IKE 1Q FY26 Performance Update
July 29th Morning Report
General Capital Annual Shareholders Meeting Results
MEE - Receivers and Liquidators appointed to King Honey
2 Cheap Cars Group Updates Performance Outlook for FY26
Spark announces Director changes as part of Board renewal
July 28th Morning Report
KMD Brands announces new Group Chief Financial Officer
Commerce Commission to issue SOI re Viridian application
FBU - Moody's affirms FBU Baa3/stable rating